Compugen Ltd. (CGEN)
1.99
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
1.93
-3.02%
Pre-market Jan 15, 2025, 06:22 AM EST
undefined% (undefined)
| Bid | 1.93 |
| Market Cap | 178.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.03 |
| PE Ratio (ttm) | 66.33 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.03 |
| Volume | 2,165,792 |
| Avg. Volume (20D) | 437,796 |
| Open | 1.97 |
| Previous Close | 1.99 |
| Day's Range | 1.95 - 2.16 |
| 52-Week Range | 1.35 - 3.03 |
| Beta | undefined |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 68
Stock Exchange NASDAQ
Ticker Symbol CGEN
Website https://cgen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 101.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Compugen Ltd. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of $24.96M, reflecting a -25.4% YoY shrinking and earnings per share of -0.07, making a -163.64% decrease YoY.
Analysts project revenue of $24.96M, reflecting a -25.4% YoY shrinking and earnings per share of -0.07, making a -163.64% decrease YoY.
10 months ago ·
Source
-13.56%
Compugen shares are trading lower after the compan...
Unlock content with
Pro Subscription
